用于癌症治疗的蛋白激酶抑制剂的问题与进展

Issues and progress with protein kinase inhibitors for cancer treatment.

作者信息

Dancey Janet, Sausville Edward A

机构信息

Division of Cancer Treatment and Diagnosis, Cancer Therapy Evaluation Program, Investigational Drug Branch, National Cancer Institute, 6130 Executive Blvd, Room 7131, Rockville, Maryland 20852, USA.

出版信息

Nat Rev Drug Discov. 2003 Apr;2(4):296-313. doi: 10.1038/nrd1066.

DOI:10.1038/nrd1066

PMID:12669029

Abstract

Identification of the key roles of protein kinases in cancer has led to extensive efforts to develop kinase inhibitors for the treatment of a wide range of cancers, and more than 30 such agents are now in clinical trials. Here, we consider the crucial issues in the development of kinase inhibitors for cancer, and discuss strategies to address the challenges raised by these issues in the light of preclinical and clinical experiences so far.

摘要

对蛋白激酶在癌症中的关键作用的识别促使人们为开发用于治疗多种癌症的激酶抑制剂付出了巨大努力，目前有30多种此类药物正在进行临床试验。在此，我们考虑开发癌症激酶抑制剂过程中的关键问题，并根据迄今为止的临床前和临床经验，讨论应对这些问题所带来挑战的策略。